[1] |
王燕忠, 丁丽敏, 陈一瑞, 等. miRNA-21-5p对食管癌的诊断价值及其与STAT3的相关性研究[J]. 检验医学, 2020, 35(6):531-534.
DOI
|
[2] |
HOLLECZEK B, SCHÖTTKER B, BRENNER H. Helicobacter pylori infection,chronic atrophic gastritis and risk of stomach and esophagus cancer:results from the prospective population-based ESTHER cohort study[J]. Int J Cancer, 2020, 146(10):2773-2783.
|
[3] |
SCHLOTTMANN F, DREIFUSS N H, PATTI M G. Obesity and esophageal cancer:GERD,barrett's esophagus,and molecular carcinogenic pathways[J]. Expert Rev Gastroenterol Hepatol, 2020, 14(6):425-433.
|
[4] |
杨勇. SCC-Ag、CA19-9、VEGF在晚期食管鳞癌化疗疗效判断中的价值[J]. 检验医学, 2021, 36(1):20-24.
DOI
|
[5] |
SENDI H, YAZDIMAMAGHANI M, HU M, et al. Nanoparticle delivery of miR-122 inhibits colorectal cancer liver metastasis[J]. Cancer Res, 2022, 82(1):105-113.
|
[6] |
CHE J, LIU M, LV H. Dexmedetomidine disrupts esophagus cancer tumorigenesis by modulating circ_0003340/miR-198/HMGA2 axis[J]. Anticancer Drugs, 2022, 33(5):448-458.
|
[7] |
MA Z, LI K, CHEN P, et al. MiR-134,mediated by IRF1,suppresses tumorigenesis and progression by targeting VEGFA and MYCN in osteosarcoma[J]. Anticancer Agents Med Chem, 2020, 20(10):1197-1208.
|
[8] |
ABDUL-MAKSOUD R S, ELSAYED R S, ELSAYED W S H, et al. Combined serum miR-29c and miR-149 expression analysis as diagnostic genetic markers for colorectal cancer[J]. Biotechnol Appl Biochem, 2021, 68(4):732-743.
|
[9] |
MORGAN E, SOERJOMATARAM I, RUMGAY H, et al. The global landscape of esophageal squamous cell carcinoma and esophageal adenocarcinoma incidence and mortality in 2020 and projections to 2040:new estimates from GLOBOCAN 2020[J]. Gastroenterology, 2022, 163(3):649-658.
|
[10] |
UHLENHOPP D J, THEN E O, SUNKARA T, et al. Epidemiology of esophageal cancer:update in global trends,etiology and risk factors[J]. Clin J Gastroenterol, 2020, 13(6):1010-1021.
|
[11] |
SHARMA P, SHAHEEN N J, KATZKA D, et al. AGA clinical practice update on endoscopic treatment of barrett's esophagus with dysplasia and/or early cancer:expert review[J]. Gastroenterology, 2020, 158(3):760-769.
|
[12] |
JING C, YAN L, WEI Z, et al. Exogenous delivery of microRNA-134(miR-134)using α-tocopherol-based PEGylated liposome for effective treatment in skin squamous cell carcinoma[J]. Drug Deliv Transl Res, 2021, 11(3):1000-1008.
|
[13] |
罗康维. 血清中miR-21和miR-134的表达情况对乳腺癌的诊断价值[J]. 中国处方药, 2020, 18(6):147-148.
|
[14] |
陈艳丹, 岑瑞祥, 曹炜, 等. miR-134靶向基质金属蛋白酶1对喉癌细胞的增殖、凋亡、侵袭和迁移的影响[J]. 重庆医学, 2021, 50(22):3793-3796.
|
[15] |
SÁNCHEZ-GONZÁLEZ I, BOBIEN A, MOLNAR C, et al. MiR-149 suppresses breast cancer metastasis by blocking paracrine interactions with macrophages[J]. Cancer Res, 2020, 80(6):1330-1341.
|
[16] |
徐海霞, 伊碧霞, 胡娥. 干扰DBH-AS1上调miR-149抑制子宫内膜癌细胞增殖、迁移与侵袭[J]. 中国优生与遗传杂志, 2021, 29(11):1538-1543.
|
[17] |
刘晓柱, 李银凤. miR-149抑制结直肠癌细胞迁移的分子机制研究[J]. 天津医药, 2020, 48(1):19-24.
|
[18] |
王珣, 曾会, 陈志娟, 等. 肝癌组织miR-146b-5p和miR-134的表达下调及临床意义[J]. 西部医学, 2021, 33(5):752-755.
|
[19] |
才让, 王永芹, 祁蕙燕, 等. miR-138、miR-149表达与非肌层浸润性膀胱癌患者临床病理特征及预后的关系[J]. 广西医科大学学报, 2021, 38(8):1552-1556.
|